Swiss National Bank Has $1.57 Million Stake in Eagle Pharmaceuticals Inc (EGRX)

Share on StockTwits

Swiss National Bank lifted its position in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 45.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,500 shares during the period. Swiss National Bank owned about 0.14% of Eagle Pharmaceuticals worth $1,566,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Meeder Asset Management Inc. increased its stake in shares of Eagle Pharmaceuticals by 232.6% in the second quarter. Meeder Asset Management Inc. now owns 1,866 shares of the specialty pharmaceutical company’s stock worth $141,000 after purchasing an additional 1,305 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter worth $150,000. Matarin Capital Management LLC purchased a new stake in shares of Eagle Pharmaceuticals in the first quarter worth $208,000. US Bancorp DE increased its stake in shares of Eagle Pharmaceuticals by 191.9% in the second quarter. US Bancorp DE now owns 2,767 shares of the specialty pharmaceutical company’s stock worth $209,000 after purchasing an additional 1,819 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals in the first quarter worth $212,000.

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald set a $81.00 price objective on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 24th. TheStreet raised shares of Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Thursday, August 9th. Royal Bank of Canada set a $84.00 target price on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 8th. Piper Jaffray Companies set a $88.00 target price on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 7th. Finally, BidaskClub cut shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Eagle Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $86.67.

EGRX opened at $66.66 on Friday. The firm has a market cap of $1.01 billion, a P/E ratio of 19.78 and a beta of 1.31. Eagle Pharmaceuticals Inc has a fifty-two week low of $48.84 and a fifty-two week high of $85.66. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.22 and a quick ratio of 4.09.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.80 by $0.15. The company had revenue of $59.30 million during the quarter, compared to analysts’ expectations of $51.78 million. Eagle Pharmaceuticals had a net margin of 13.81% and a return on equity of 19.71%. research analysts predict that Eagle Pharmaceuticals Inc will post 2.15 EPS for the current year.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Recommended Story: NASDAQ

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply